PFIZi019-A

RCi202, BC145c6

iPSC line

At European Collection of Authenticated Cell Cultures (ECACC)
Timepoint: 24hr post thaw
Magnification: X4
Timepoint: 24hr post thaw
Magnification: x10
Timepoint: Confluency
Magnification: x4
Timepoint: Confluency
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg Name PFIZi019-A
Alternative name(s)
RCi202, BC145c6
Cell line type Human induced pluripotent stem cell (hiPSC)

Provider

Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)

External Databases

hPSCreg PFIZi019-A
BioSamples SAMEA4458852
ECACC 66540420
Cellosaurus CVCL_RF98
CLO CLO_0101659
Wikidata Q54947274

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed

Donor Information#

General Donor Information

Sex male
Age of donor (at collection) 5-9

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Dravet syndrome
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMEI
  • Severe myoclonus epilepsy of infancy
  • Severe myoclonic epilepsy of infancy
Genetic variants
SCN1A (target)
2q24.3
SCN1A Variant 1:1 bp deletion of T ; Nucleotide Postion 4522' Codon Position: 1508; Amino Acid Change- Frame Shift
Disease associated phenotypes
  • Myoclonic seizures
  • Slightly wide-based gait, intermittent ataxia

External Databases (Donor)

BioSamples SAMEA4458853

hIPSC Derivation#

General

Source cell type
erythroblast
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
  • normoblast
Age of donor (at collection) 5-9

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium Essential 8
Passage method EDTA
Surface coating Matrigel / Geltrex
O2 concentration 21
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
SSEA-1
No
TRA 1-60
Yes
SSEA-4
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
SOX17
Yes
GATA6
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
MIXL1
Yes
NCAM1
Yes
VIM
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
HES5
Yes
NeuroD1
No

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No autosomal or sex chromosome aneuploidies were detected
Passage number: 19
Karyotyping method: KaryoLite BoBs

Other Genotyping (Cell Line)